Overview

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Status:
Completed
Trial end date:
2012-02-21
Target enrollment:
Participant gender:
Summary
A drug-drug interaction study to investigate the potential pharmacokinetic interaction between MDV3100 and a cocktail of substrates for pioglitazone (CYP2C8 substrate), S-warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate).
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Europe B.V.
Collaborator:
Medivation, Inc.
Treatments:
Midazolam
Omeprazole
Pioglitazone
Warfarin